Jake Strole
EUR 850.00 For Business Accounts Only

Morningstar | Unexpected CEO Departure Doesn't Weaken Our Exemplary Stewardship Rating

Cantel Medical’s business has been transformed through acquisition since its breakup with former partner Olympus back in 2006, when both sides broke off distribution agreements with the goal of going direct in their respective markets. Since then, management’s strategy of buying regional businesses and scaling them nationally has thrived, with the firm now positioned as the leader in endoscope reprocessing and central water treatment for dialysis clinics across the country. This approach has built two narrow-moat business segments, in our view, that represent over 75% of total company sales and are underpinned by customer switching costs and intangible assets.The company’s strategy has been to extend its reach within the sprawling area of infection prevention and augment its market position through strategic mergers and acquisitions. Management has allocated over $300 million toward its acquisition strategy over the past five years, all while expanding the firm’s margin profile and increasing returns on capital for shareholders. We expect an additional $400 million will be spent over the coming five years as Cantel more decisively develops its international presence. We anticipate this strategy will remain value-accretive as management continues to source synergistic deals at reasonable valuations, while maintaining a conservative balance sheet structure.We expect the firm to generate returns on invested capital in excess of its weighted average cost of capital over the coming decade, owing to the switching costs that have been embedded within its customer relationships and the preeminent brands it has developed in the endoscopy and water treatment end markets. The long life of its products, along with proprietary consumables and service components, have created repeat customer engagements and relationships that we believe are deep enough to signal the existence of a moat. Additionally, the firm’s demonstrated pricing power in the market, while pricing new product platforms at material premiums, supports our view that the company possesses intangible assets that aid in supporting its moat.
Cantel Medical Corp.

Cantel Medical is a provider of infection prevention products and services in the healthcare market. The company has four segments: Medical, which designs, develops, manufactures, sells and installs products and services comprising a circle of infection prevention solutions; Life Sciences, which designs, develops, manufactures, sells, and installs water purification systems; Dental, which designs, manufactures, sells, supplies and distributes infection prevention healthcare products; and Dialysis, which designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers, as well as dialysate concentrates and supplies utilized for renal dialysis


Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Jake Strole

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch